DURECT Corp (NASDAQ:DRRX)
| 4.61 Delayed Data As of 3:59pm ET |  -0.03 / -0.65%Today’s Change | 3.17 Today|||52-Week Range 9.70 | +33.24% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $115.1M |
Company Description
DURECT Corp. focuses on advancing novel and potentially lifesaving investigational therapies derived from its Epigenetic Regulator Program. Its pipeline is called DUR-928, an endogenous sulfated oxysterol and an epigenetic regulator. The company was founded by James E. Brown and Felix Theeuwes on February 6, 1998 and is headquartered in Cupertino, CA.
Contact Information
DURECT Corp. 10260 Bubb Road Cupertino California 95014-4166 |
Employees
Shareholders
| Mutual fund holders | 6.45% |
| Other institutional | 32.92% |
| Individual stakeholders | 10.77% |
Top Executives
| James E. Brown | President, Chief Executive Officer & Director |
| Judy R. Joice | Senior VP-Operations & Corporate Quality Assurance |
| Timothy M. Papp | Chief Financial Officer & Secretary |
| Wei Qi Lin | Executive Vice President-Research & Development |
| David J. Ellis | Vice President-Clinical Development |
